- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.
| Popular Stocks | Price | Change |
|---|---|---|
|
C
|
$8.82
 20.85%
|
20.85% |
|
$2.27
3.18%
|
3.18% |
|
$134.16
0.17%
|
0.17% |
|
$36.09
4.21%
|
4.21% |
|
$39.15
 0.08%
|
0.08% |
|
$43.84
2.12%
|
2.12% |
|
$38.57
1.58%
|
1.58% |
|
$27.24
5%
|
5% |
|
$13.39
1.83%
|
1.83% |
|
$82.15
0.58%
|
0.58% |
News
Connect
People who are active on baraka tribe community
Stock Analysis
